Medical Device Front-Panel RFQ: Define Material Identity Before a PFAS Claim

For a medical-device front panel, tie each material statement to the supplied layer, exact grade, document revision and affected component lot. When a supplier changes a processing aid, record what changed in the process and what remains in the delivered construction. A process statement does not by itself describe every substance in a finished panel. Define the evidence boundary before accepting a PFAS claim or approving a substitute in a graphic overlay or front-panel assembly.

Record the scope of a processing-aid change

On 2026-10-21, Freudenberg Sealing Technologies described new food-industry sealing materials made with polymers produced without fluorosurfactants. Its release distinguishes replacement of processing aids from replacement of the fluoropolymers themselves. It also describes individual material evaluation and coordination with affected customers. The described process change leaves the fluoropolymer in place.

The announcement concerns food and beverage seals. It does not approve those materials for a medical front panel, identify Baoshengda's materials or establish a supply relationship. The sourcing lesson is about the scope of a change notice: “without fluorosurfactants” and a claim about all substances in the delivered component answer different questions.

For a front-panel buyer, the next step is to ask which film, coating, ink, adhesive or other supplied layer a statement covers. Request the old and proposed identities, affected revisions and supporting documents. Do not carry a declaration for one upstream process across an entire multilayer panel. Retain any unverified layers as open items for the responsible reviewer.

Keep the medical-device assessment separate

The original guide's FDA PFAS in Medical Devices page, updated 2026-09-01, remains useful background. It distinguishes fluoropolymers used in devices from smaller PFAS linked to environmental concerns and explains that the FDA regulates finished devices, not individual materials in isolation. Use and body contact affect the assessment.

That background is not an approval of an overlay, ink or adhesive. The device manufacturer must decide which evidence is appropriate for its intended use, contact conditions and markets. Keep the component declaration, physical sample acceptance and finished-device assessment as separate decisions. The retained illustration and a film's appearance cannot establish chemical identity or a safety conclusion.

Make a layer-specific change record

Give every supplied layer a controlled identifier. A panel may include PET or polycarbonate face film, printed color and opaque layers, a clear window, hard coat, pressure-sensitive adhesive, release liner, spacers and a flexible circuit. Include only the layers actually supplied. Identify a liner removed during assembly separately from materials remaining in the installed device.

Use the released bill of materials as the starting point. Add supplier and grade information where it can be disclosed, plus a stable reference to any controlled confidential record. A record that says only “PET,” “adhesive” or “equivalent” leaves purchasing unable to relate the document to the delivered construction.

This is a blank record structure for an agreed project, not a completed declaration or test result. Do not invent a formulation or an analytical result to fill an empty cell. If an upstream document is unavailable, record the gap and its owner so the device team can decide whether more evidence is needed.

Agree what the declaration actually says

A supplier statement should name the supplied article and the material list it covers. Record its definition, exclusions, document revision, date and evidence basis. “Not declared,” “not intentionally added,” “not known from the available upstream document” and “outside supplied scope” are not interchangeable answers.

Ask whether the statement concerns a manufacturing process, intentionally added ingredients, an identified substance list or an analytical measurement. If testing is offered, the responsible reviewer should confirm the sample identity, method, reporting limit and scope before interpreting the result. A test limited to one layer or a selected substance list should retain those limits in the purchasing record.

Assign an owner to each gap. The component supplier can obtain or reference upstream information within its scope. The device manufacturer's qualified reviewers decide whether that evidence supports the intended assessment and any finished-device claim. A change in wording alone does not establish that a physical material changed, and an unchanged grade name does not explain a notified process change.

Recheck the physical functions affected by a substitute

A material statement and a functional sample answer different questions. Two transparent films can look alike but differ in print adhesion, surface finish, optical haze or flex behavior. Similar-looking adhesives may bond differently to the approved housing. Compare the proposed construction with the released component using the actual functions and exposure conditions.

At drawing review, preserve the perimeter, window active area and border, key locations, print registration, texture, embossing, adhesive pattern, tail exit and connector position. Tie the stack table to the drawing revision. Review adhesive-free and clear-window zones, housing material, coating, roughness, curvature and available landing support.

At sample review, check window clarity, color and artwork alignment, surface texture, adhesive coverage, edge lift, housing fit and the cleaning exposure defined by the device team. When keys are included, repeat mounted actuation and release checks. For an included flexible circuit, check tail bend, contact exposure, insertion depth, continuity and connector retention. These checks establish construction and function; they do not identify PFAS by sight.

Retain the sample lot, inspection conditions and matching evidence package. Define notification requirements for changes to film grade, hard coat, ink, adhesive, liner, circuit substrate, connector or manufacturing site. Record what needs new documents, what needs new samples and who can approve release. Preserve earlier revisions instead of replacing their supporting records with the latest file.

Start with the question and documents you have

An available panel photo or sketch, intended use, approximate quantity or an unresolved material statement can start a front-panel material review. Attach an existing drawing or supplier declaration if available. A complete production drawing package is not required for the first inquiry.

Before a firm quotation or sample release, close the controlled artwork, dimensions, window requirements, layer stack, surface finish, adhesive and housing interface. Include any keys, tail or connector in that construction record.

Attach the cleaning and contact conditions, requested declaration wording and exclusions, and the change record. Agree the sample and acceptance plan, quantities, packaging, service-spare needs and retention requirements.

Baoshengda can review the agreed graphic overlay or membrane-interface construction, supplied materials, manufacturing operations and inspection evidence. Device-level biological or toxicological evaluation where applicable, contact classification, cleaning validation, electrical safety, software and regulatory decisions remain with the medical-device manufacturer.

The retained image is a generated illustration of an overlay, lifted corner, sample films and a complete tail above an open housing. It is not a customer device, chemical analysis, factory inspection or verified test result.